Verastem Inc.'s gamble late in 2016 on the late-stage hematologic cancer candidate duvelisib appears to be paying off, as the biotech unveiled positive Phase III data Sept. 6 for the PI3K inhibitor in a head-to-head study against ofatumumab in patients with refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Top-line data from the open-label, randomized DUO trial show that monotherapy with duvelisib – which would be the first dual inhibitor of phosphoinositide 3-kinase delta and gamma – offers a 48% reduction of risk of disease progression or death compared to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
